Escape

Round double-branded tablets coated with a white or almost white film shell, with a faint smell of ammonia, on white or almost white.

functional dispersion not related to organic diseases of the gastrointestinal tract ;

chronic gastritis and gastroduodenitis in the phase of exacerbation, including.h. associated with Helicobacter pylori;

peptic ulcer of the stomach and duodenum in the phase of exacerbation, including.h. associated with Helicobacter pylori;

irritable bowel syndrome, occurring mainly with symptoms of diarrhea.

Inside, 30 minutes before eating, drinking a little water. It is recommended to swallow the tablet in its entirety without chewing or grinding. It is not recommended to drink pills with milk. The duration of the course of treatment and the dose of the drug is determined by the attending physician individually for each patient, depending on the nature of the disease.

Adults and children over 12 years old are prescribed 1 tablet each. 4 times a day, 30 minutes before eating (breakfast, lunch, dinner) and at night, or 2 tablets each. 2 times a day, 30 minutes before eating (breakfast dinner).

Children from 8 to 12 years old are assigned 1 table each. 2 times a day, 30 minutes before eating (breakfast, dinner); from 4 to 8 years - 8 mg / kg / day (depending on the mass of the child’s body, 1–2 tablets are prescribed./ day (respectively in 1-2 doses per day). In this case, the daily dose should be closest to the estimated dose (8 mg / kg / day).

The duration of the course of treatment is usually from 4 to 8 weeks. After taking the drug, it is not recommended to take drugs containing bismuth (for example, Vikalin, Vikair) for 2 months.

For eradaptation Helicobacter pylori it is advisable to use the vismut tricali of dicitrate in combination with antibacterial drugs with antichelicobacter activity.

increased individual sensitivity to the components of the drug ;

pregnancy;

period of breastfeeding ;

taking drugs containing bismuth ;

chronic renal failure ;

childhood up to 4 years.

The following undesirable phenomena noted when applying the tricitrate tricutas are distributed according to the frequency of occurrence in accordance with the following gradation: very often (≥1/10); often (≥1/100, <1/10); infrequently (≥1/1000, <1/100); rarely (≥1/10000,.

From the side of the LCD : very often - staining feces in black; infrequently - nausea, vomiting, diarrhea or constipation.

Allergic reactions : infrequently - skin rash, itching; very rarely - anaphylactic reactions.

From the side of the nervous system : very rarely (with prolonged use in high doses) - encephalopathy associated with the accumulation of vismut in the central nervous system.

Side effects are reversible and quickly pass after the drug is canceled.

Symptoms : (when using the drug in doses tens of times higher than recommended, or with prolonged use of high doses of the drug), it is possible to develop vismutum poisoning - dyspepsia, rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums; kidney function may be impaired. These symptoms are completely reversible when canceling the drug.

Treatment: there is no specific antidote. An overdose of the drug shows gastric lavage, taking enterosorbents and symptomatic therapy aimed at maintaining kidney function. In case of overdose, the purpose of salt laxatives is also shown. Further treatment should be symptomatic. In case of impaired renal function, accompanied by a high level of vismut in the blood plasma, complex converters can be introduced - dimercaptoantar and dimercaptopropan sulfonic acid. With the development of severe impaired renal function, hemodialysis is shown.

Gastroprotector and antidrase with bactericidal activity in relation Helicobacter pylori.  It also has anti-inflammatory and astringent effects.

In the acidic environment of the stomach, insoluble vismuta oxychloride and citrate are precipitated, chelate compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosion. Thus, the drug forms a protective layer, which for a long period of time protects the affected areas of the mucous membrane from the influence of aggressive factors. Increasing the synthesis of PGE, the formation of mucus and the secretion of hydrocarbonate, stimulates the activity of cytoprotectory mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsiin, hydrochloric acid, enzymes and bile acid salts. It leads to the accumulation of the epidermal growth factor in the defect zone. Reduces the activity of pepsin and pepsinogen.

Almost not absorbed from the LCD. It is derived mainly with feces. A small amount of vismut, received in plasma, is excreted by the kidneys.

For half an hour before and half an hour after taking the drug, it is not recommended to use other drugs inside, as well as eating food and liquid, in particular antacids, milk, fruits and fruit juices. This is due to the fact that they can simultaneously take inward the effectiveness of the vismut tricali of dicitrate.

The drug reduces the absorption of tetracycline.

The drug is not used simultaneously with other drugs containing bismuth, t.to. the simultaneous use of several vismut preparations increases the risk of developing side effects, including.h. risk of developing encephalopathy.

• Anti-invited agent, antiseptic intestinal and astringent [Gastroprotectors]

Keep out of the reach of children.

Do not apply after the expiration date indicated on the package.

Tablets coated with a film shell, 120 mg. 10 or 14 tablets each. in contour cell packaging made of PVC film and aluminum printed lacquered foil. 2, 4, 8 or 16 contour cell packages are placed in a cardboard pack.

The vismuta tricalia dicitrate is contraindicated for use in pregnant women. If it is necessary to use the drug during lactation, breastfeeding should be stopped.

Uncounter.

The drug should not be used for more than 8 weeks. It is not recommended to exceed the established per diem doses for adults and children during treatment. During treatment, the drug should not use other drugs containing bismuth (see. "Interaction"). At the end of course treatment with the drug in the recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 μg / L, and intoxication is observed only at a concentration above 100 μg / L.

When applying the bismuth of tricalium of dicitrate, it is possible to dye the fecal in dark due to the formation of the sulfide of the vismut.

Sometimes there is a slight darkening of the language.

Alcohol is not recommended during therapy.

Impact on the ability to drive vehicles and mechanisms. Data on the effect of the drug Escape^®, tablets covered with a film shell, there is no ability to drive vehicles and mechanisms.

• K25 Vastric ulcer
• K26 Twin bowel ulcer
• K29.5 Chronic gastritis unspecified
• K29.9 Gastroduodenitis unspecified
• K30 Dispatch
• K58.0 Syndrome of irritated intestines with diarrhea
• K59.1 Functional diarrhea